
Opus Genetics (IRD) Stock Forecast & Price Target
Opus Genetics (IRD) Analyst Ratings
Bulls say
Opus Genetics is expected to see strong growth in the future due to their innovative gene therapy pipeline, potential for profitability through royalties and milestones, and expansion opportunities through rare retinal disease treatments and new methods of gene delivery. Their strong partnerships and funding also bode well for their future success.
Bears say
Opus Genetics is currently in a strong position with a portfolio of seven AAV-based programs targeting IRDs, and potential first-mover advantage. However, their reliance on the success of their two lead gene therapy programs, OPGx-LCA5 and OPGx-BEST1, also poses significant risk to their business. With a heavy focus on clinical development and limited commercialization experience, Opus may struggle to effectively market and commercialize their products if they are successfully approved. Additionally, there are other risks to consider such as potential competition, intellectual property challenges, and financial constraints. Overall, despite the potential for a large market opportunity, the risks associated with Opus Genetics make their stock outlook negative.
This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.
Opus Genetics (IRD) Analyst Forecast & Price Prediction
Start investing in Opus Genetics (IRD)
Order type
Buy in
Order amount
Est. shares
0 shares